Posted by Michael Wonder on 28 Oct 2023
ImmunoGen announces European Medicines Agency acceptance of marketing authorisation application for mirvetuximab soravtansine in platinum-resistant ovarian cancer
27 October 2023 - ImmunoGen today announced that the EMA has accepted the marketing authorisation application for mirvetuximab soravtansine (Elahere) for the treatment of patients with folate receptor alfa positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer.
The application is supported by positive data from the Phase 3 MIRASOL trial of Elahere in platinum-resistant ovarian cancer, which was disclosed in May 2023 and subsequently presented as a late-breaking abstract at the 2023 American Society of Clinical Oncology Annual Meeting.
